157 related articles for article (PubMed ID: 10746808)
1. Erythropoietin and arterial hypertension.
Luft FC
Clin Nephrol; 2000 Feb; 53(1 Suppl):S61-4. PubMed ID: 10746808
[TBL] [Abstract][Full Text] [Related]
2. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).
Krapf R; Hulter HN
Clin J Am Soc Nephrol; 2009 Feb; 4(2):470-80. PubMed ID: 19218474
[TBL] [Abstract][Full Text] [Related]
3. Management of blood pressure changes during recombinant human erythropoietin therapy.
Levin N
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):16-20. PubMed ID: 2669081
[TBL] [Abstract][Full Text] [Related]
4. Changes in diurnal blood pressure variation and red cell and plasma volumes in patients with renal failure who develop erythropoietin-induced hypertension.
Jones MA; Kingswood JC; Dallyn PE; Andrew M; Cheetham A; Burwood R; Sharpstone P
Clin Nephrol; 1995 Sep; 44(3):193-200. PubMed ID: 8556836
[TBL] [Abstract][Full Text] [Related]
5. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
6. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
Korbet SM
Kidney Int Suppl; 1993 Feb; 40():S111-9. PubMed ID: 8445832
[No Abstract] [Full Text] [Related]
7. Blood rheology in hemodialysis patients treated with recombinant human erythropoietin.
Brunner R; Pollok M; Heidel M; Müller R; Degenhardt S; Baldamus CA
Contrib Nephrol; 1989; 76():306-12; discussion 312-4. PubMed ID: 2582784
[No Abstract] [Full Text] [Related]
8. Blood pressure increase after erythropoietin injection in hemodialysis and predialysis patients.
Noshad H
Iran J Kidney Dis; 2013 May; 7(3):220-5. PubMed ID: 23689155
[TBL] [Abstract][Full Text] [Related]
9. r.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline.
Tapolyai M; Kadomatsu S; Perera-Chong M
BMC Nephrol; 2003 Jun; 4():3. PubMed ID: 12809563
[TBL] [Abstract][Full Text] [Related]
10. Anemia in renal insufficiency.
Santoro A
Rev Clin Exp Hematol; 2002; Suppl 1():12-20. PubMed ID: 12735211
[TBL] [Abstract][Full Text] [Related]
11. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
Radermacher J; Koch KM
Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
[TBL] [Abstract][Full Text] [Related]
12. [Optimal therapy with erythropoietin (EPO) in patients with renal anemia on hemodialysis therapy].
Merta M; Sobotová D; Zahálková J; Bitterová Z; Jirka T; Knetl P; Kopenec J; Suchanová J; Vlasák J
Sb Lek; 2001; 102(1):41-52. PubMed ID: 11830918
[TBL] [Abstract][Full Text] [Related]
13. [Evolution of medical practice in the care of anemia amd the use of erythropoietin in chronic renal insufficiency hemodialysis in the past six years].
Canaud B; Richard A; Fagnani F; Moreau-Defarges T; Guillon P
Nephrologie; 2002; 23(3):123-30. PubMed ID: 12087809
[TBL] [Abstract][Full Text] [Related]
14. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
15. Role of oxidative stress in erythropoietin-induced hypertension in uremic rats.
Rancourt ME; Rodrigue ME; Agharazii M; Larivière R; Lebel M
Am J Hypertens; 2010 Mar; 23(3):314-20. PubMed ID: 20019674
[TBL] [Abstract][Full Text] [Related]
16. Hypertension induced by erythropoietin has a correlation with truncated erythropoietin receptor mRNA in endothelial progenitor cells of hemodialysis patients.
Ioka T; Tsuruoka S; Ito C; Iwaguro H; Asahara T; Fujimura A; Kusano E
Clin Pharmacol Ther; 2009 Aug; 86(2):154-9. PubMed ID: 19458615
[TBL] [Abstract][Full Text] [Related]
17. [Erythropoietin: from established therapeutic procedures in renal anemia to future areas of use].
Marsen TA; Pollok M; Baldamus CA
Med Klin (Munich); 1992 Apr; 87(4):207-14. PubMed ID: 1579099
[No Abstract] [Full Text] [Related]
18. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
19. Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients?
Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
Nephrology (Carlton); 2006 Oct; 11(5):394-9. PubMed ID: 17014551
[TBL] [Abstract][Full Text] [Related]
20. Indications and contraindications for recombinant human erythropoietin treatment. Results in hemodialysis patients.
Samtleben W; Baldamus CA; Bommer J; Grützmacher P; Nonnast-Daniel B; Scigalla P; Gurland HJ
Contrib Nephrol; 1989; 76():193-200; discussion 212-8. PubMed ID: 2684521
[No Abstract] [Full Text] [Related]
[Next] [New Search]
